Semaglutide sodium and acetate: why FDA distinguishes salt forms from the base

01

A salt form is not just another label for the approved ingredient

Drug names can make related substances appear interchangeable when they are not. FDA states that semaglutide sodium and semaglutide acetate are salt forms and are different active ingredients from the semaglutide base used in FDA-approved drugs. The distinction concerns chemical identity, not branding preference.

FDA also says it does not have information showing that the salts have the same chemical and pharmacologic properties as the active ingredient in approved drugs. That means an editor, clinic, or pharmacy should not shorten “related to semaglutide” into “the same active ingredient” without product-specific support.

A chemical salt can differ in composition and other characteristics relevant to manufacturing and drug performance. This guide does not attempt to predict how a particular salt product behaves in a person. The evidence-based conclusion is narrower: FDA does not recognize the salts as the active ingredient used in approved semaglutide drugs.

02

FDA says it is not aware of a lawful compounding basis for the salts

FDA’s current GLP-1 concerns page says salt forms should not be used to compound semaglutide. The agency states that it is not aware of any lawful basis for their use in compounding. Its separate dosing-error alert likewise says it is not aware of a basis that would meet the FD&C Act conditions governing the active ingredients compounders may use.

This wording is stronger than saying a salt is simply off-label. Off-label prescribing involves an FDA-approved finished drug used outside parts of its labeling. A preparation made from a different bulk active ingredient is a separate product and raises the ingredient-eligibility conditions of sections 503A or 503B.

A provider should not answer the concern by saying the salts are pharmaceutical grade, accompanied by a certificate of analysis, or dispensed under a prescription. Those facts do not by themselves satisfy the federal bulk-substance conditions, prove equivalence to the approved base, or create FDA approval.

03

The 503A and 503B ingredient pathways ask different questions

Under section 503A, FDA’s comparison chart says a bulk substance generally must meet an applicable USP or National Formulary monograph, be a component of an FDA-approved drug when no such monograph exists, or appear on the 503A Bulks List, in addition to other conditions. A valid certificate of analysis and a registered bulk-substance manufacturer are also part of the federal framework.

Under section 503B, an outsourcing facility generally may use a bulk substance only when the substance appears on the 503B clinical-need list or when the drug compounded from it is on FDA’s shortage list at the required times, again subject to other conditions. Registration as an outsourcing facility is not permission to use any ingredient.

FDA’s April 2026 update said semaglutide was not on the 503B Bulks List or the drug shortage list. FDA also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B list after finding no clinical need for outsourcing facilities to compound from those bulk substances. The proposal and a salt-form problem are related regulatory context, but they are not the same issue.

04

Shortage and “essentially a copy” rules do not cure a salt-form problem

Semaglutide injection shortage status has affected when certain compounded copies could qualify for enforcement discretion or statutory pathways. FDA announced the shortage resolved in February 2025 and later clarified that the relevant transition periods had ended. Current shortage status remains a date-sensitive fact that should be checked directly.

FDA’s 503A copy policy focuses on whether a compounded drug is regularly or inordinately made as essentially a copy of a commercially available drug, subject to limited circumstances such as a documented significant difference for an identified patient. The agency’s 503B framework separately restricts products that are identical or nearly identical to approved drugs.

Using a different active ingredient does not provide a simple workaround. A salt form may fail the bulk-substance conditions, while a base-form product may raise shortage and copy questions. A provider should identify and support both the ingredient pathway and the reason the specific compounded product is being considered.

05

How to read a label or pharmacy answer about semaglutide form

Start with the exact active ingredient line, not the program name. Ask whether the bulk substance was semaglutide base, semaglutide sodium, semaglutide acetate, or another form. If the response says only “semaglutide,” request the full chemical identity as it appears on the ingredient documentation and finished-product record.

Then match the pharmacy’s legal name and address with state records and, if it claims 503B status, FDA’s outsourcing-facility registry. Ask whether the pharmacy compounded the product itself, which entity manufactured the bulk ingredient, and which current statutory condition it relies on. An NDC, facility registration, or accreditation badge does not answer the ingredient question.

Do not use a label investigation to calculate or change a dose. FDA has reported serious dosing errors involving variable concentrations, multidose vials, and unit conversions with compounded semaglutide. When a label is unclear or conflicts with what was prescribed, contact the dispensing pharmacist and prescriber before use.

• →Exact active ingredient and chemical form
• →Compounder’s legal name and address
• →503A or 503B pathway claimed
• →Bulk manufacturer and certificate matched to the ingredient
• →Concentration and total amount stated clearly
• →Prescriber and pharmacist available to resolve conflicts

06

Risk, uncertainty, and provider marketing require separate checks

FDA says unapproved GLP-1 versions do not undergo its premarket review for safety, effectiveness, or quality. The agency has also described fraudulent labels, variable concentrations, dosing errors, and adverse-event reports involving compounded semaglutide. None of those records proves that every product has the same defect, but they show why identity and source cannot be assumed.

Marketing phrases such as same molecule, bioidentical, generic, clinically proven, or FDA-registered should be tested against the exact product. FDA-approved generics require approved applications; compounded drugs are not generics. A registered establishment or listed product is not automatically FDA-approved.

People considering or using a prescription drug should discuss product identity and treatment decisions with appropriately licensed clinicians and pharmacists. Suspected medication errors or adverse events can be reported through FDA MedWatch. Seek urgent medical care for an emergency rather than waiting for a directory, clinic sales team, or general message form.